Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Eskender Getachew

Sleep Medicine Columbus, OH Medical Doctor

NPI 1033177571 CMS profile 1161423

1050 Kingsmill Pkwy, Columbus, OH 43229

Open in the dashboard

General payments

$3,931

220 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Eskender Getachew of Columbus, OH is reported in the CMS Open Payments database as having received $3,931 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $33 2
2023 General $277 10
2022 General $946 46
2021 General $1,169 73
2020 General $484 25
2019 General $1,022 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eskender Getachew
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Eskender Getachew were reported at $0. Among 263 Sleep Medicine profiles paid that year, the median was $337 and the middle half received between $114 and $1,241.

Show as a table
Year Eskender Getachew Sleep Medicine median Middle half National median
2019 $1,022 $206 $79–$855 $163
2020 $484 $170 $48–$1,437 $114
2021 $1,169 $178 $53–$1,297 $132
2022 $946 $313 $95–$1,332 $149
2023 $277 $307 $117–$1,081 $160
2024 $33 $308 $100–$1,432 $164
2025 $0 $337 $114–$1,241 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Biohaven Pharmaceutical Holding Company Ltd. $603 27 payments
  2. Jazz Pharmaceuticals Inc. $490 31 payments
  3. Biohaven Pharmaceuticals, Inc. $308 22 payments
  4. SK Life Science, Inc. $296 20 payments
  5. Biogen, Inc. $265 10 payments
  6. Merz North America, Inc. $187 5 payments
  7. Eisai Inc. $175 12 payments
  8. Galderma Laboratories, L.P. $136 3 payments
  9. AbbVie, Inc. $126 6 payments
  10. Supernus Pharmaceuticals, Inc. $125 9 payments
  11. Other $1,221 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,866 218 payments
  2. Education $66 2 payments
Products named General payments · program years 2019–2024
  1. NURTEC ODT $910 49 payments
  2. XYWAV $198 12 payments
  3. SUNOSI $191 14 payments
  4. Fycompa $175 12 payments
  5. VUMERITY $164 3 payments
  6. XYREM $150 9 payments
  7. CONTRAVE $124 8 payments
  8. TECFIDERA $124 8 payments
  9. TYSABRI $122 8 payments
  10. BOTOX $112 5 payments
  11. Other $1,657 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record